Projects from the section of Experimental Pharmacology are directed at identification of novel drug targets, developing new chemical entities to modulate these and to investigate methods to optimize existing drug therapies.
Experiments are performed in a range of model systems (cellular, animals), dealing with highly fundamental cell processes, such as quality control of proteins, energy metabolism and cellular damage pathways. Application of this knowledge is sought primarily in the area of cardiac, vascular and renal disease or complications of disease (particularly diabetes).
Research in the past years has generated fundamental insights in processes, which have been claimed in patents. From this research line and based on obstained patents, 2 Groningen-based spin-off companies have emerged (Nyken b.v., Sulfateq b.v.) that have performed lead optimization and currently hold a pipeline of active compounds being explored in various conditions. Close interaction with the department is still ongoing on a number of projects